Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Phase I Study of the Safety & Pharmacokinetics of Two Doses of CT1812 in Subjects With Mild to Moderate Alzheimer's Disease

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 12 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

27 Feb 2025 According to a Cognition Therapeutics media release, the company has published a manuscript reviewing recent work with data from an unbiased pathway analysis of CSF proteomes from AD participants treated in this study which supports the potential of zervimesine (CT1812) in The Nature Journal, Scientific Reports.
10 Feb 2021 Results presented in a Cognition Therapeutics media release.
10 Feb 2021 According to a Cognition Therapeutics media release, biomarker findings from the study have been published in Alzheimer's & Dementia: The Journal of the Alzheimer's Association.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com